Key Points
- Insider sale: Genelux insider Yong Yu sold 9,683 shares at an average price of $2.75, reducing his position by 3.61% to 258,688 shares.
- Weak financial performance: Genelux shares opened at $2.55, near their 12-month low, while the company reported a quarterly loss of $0.21 per share, slightly missing analyst expectations.
- Mixed outlook: Institutional investors own 37.33% of the stock, and analyst views range from “speculative buy” to “sell”; overall, Genelux carries a “Moderate Buy” consensus rating with an $18 price target.
Genelux Corporation (NASDAQ:GNLX - Get Free Report) insider Yong Yu sold 9,683 shares of the company's stock in a transaction on Monday, August 31st. The shares were sold at an average price of $2.75, for a total transaction of $26,628.25. Following the completion of the transaction, the insider owned 258,688 shares of the company's stock, valued at approximately $711,392. The trade was a 3.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Yong Yu also recently made the following trade(s):
- On Tuesday, August 4th, Yong Yu sold 653 shares of Genelux stock. The stock was sold at an average price of $2.94, for a total transaction of $1,919.82.
Genelux Price Performance
Shares of NASDAQ:GNLX opened at $2.55 on Thursday. Genelux Corporation has a 12 month low of $2.29 and a 12 month high of $8.53. The firm has a market capitalization of $115.37 million, a P/E ratio of -2.97 and a beta of 0.57. The company's fifty day moving average price is $2.83 and its 200 day moving average price is $2.78.
Genelux (NASDAQ:GNLX - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). On average, sell-side analysts anticipate that Genelux Corporation will post -0.81 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of GNLX. GSA Capital Partners LLP acquired a new position in Genelux in the second quarter valued at $35,000. Jefferies Financial Group Inc. acquired a new stake in shares of Genelux during the fourth quarter worth about $48,000. Squarepoint Ops LLC acquired a new stake in shares of Genelux during the fourth quarter worth about $52,000. Raymond James Financial Inc. boosted its stake in shares of Genelux by 22.6% during the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company's stock worth $83,000 after buying an additional 5,333 shares during the period. Finally, Marshall Wace LLP purchased a new position in shares of Genelux during the second quarter worth about $92,000. 37.33% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on GNLX shares. Benchmark reissued a "speculative buy" rating on shares of Genelux in a research report on Tuesday, August 18th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Genelux in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded Genelux from a "strong sell" rating to a "sell" rating in a research note on Sunday, August 23rd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Genelux presently has an average rating of "Moderate Buy" and a consensus price target of $18.00.
Get Our Latest Research Report on Genelux
Genelux Company Profile
(
Get Free Report)
Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company's programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux's lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.
Genelux's pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
